SecBot SecBot
424B5 ·Filed Nov 12, 2026

FATE

FATE THERAPEUTICS INC
BEARISH
Impact 4/10
Horizonweeks Processed4d 8h ago SEC0001193125-26-458736
Notable filing: 424B5
Actionable Insight ▼ Bearish

Monitor quarterly disclosures of shares sold under the ATM to gauge actual dilution. The company's cash runway extends to mid-2028 per Q3 2026 guidance, but the ATM signals ongoing capital needs for clinical trials of FT819 and FT839.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

FATE drug pipeline →

FT819

● Neutral Named in this 424B5
Impact
Phase
Phase 2
Time to market
FT819 is in Phase 2 testing (RECLAIM-LN, a potentially registrational trial) that began enrolling in August 2026. If successful, an FDA submission could be several years away, likely in 2028-2029 at the earliest.
Next catalyst
None dated

What to watchThe next major catalyst for FT819 is the Phase 2 RECLAIM-LN interim data expected in H2 2027. Positive data would validate the registrational trial and could drive significant upside for this single-asset-focused biotech. Negative or mixed data would be bearish. The stock trades at $1.26 with a 52-week range of $0.95-3.23. The newly effective $100M ATM facility signals potential near-term dilution risk.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$1.28
T+0 close · Nov 12, 2026 · via day close
Latest settled
−10.94%
T+1 · $1.14
Vs SPY
−9.03%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $1.28entry
  2. T+1 · 18h ago −10.94%α −9.03% · $1.14
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Fate Therapeutics filed a 424B5 prospectus supplement establishing a new $100M at-the-market (ATM) equity facility with Leerink Partners, replacing a prior ATM with Jefferies. The company had $139.1M in cash as of September 30, 2026 and is a pre-revenue clinical-stage biotech. The ATM provides ongoing capital access for pipeline development but signals continued cash needs.

Key Financial Metrics

Offering Size
$100.0M
Underwriters
Leerink Partners LLC

Key Facts

  • ATM facility of up to $100,000,000 in common stock with Leerink Partners as sales agent
  • Commission rate of up to 3.0% of gross proceeds
  • 106,155 shares already sold under prior ATM for $176,811.77 in gross proceeds
  • Last reported sale price on November 11, 2026 was $1.61 per share
  • Cash, cash equivalents and short-term investments of $139.1M as of September 30, 2026
  • Net loss of $0.25 per share in Q3 2026, no collaboration revenue
  • Prior ATM with Jefferies LLC terminated in connection with new Leerink agreement

Financial Impact

Up to $100,000,000 in potential equity issuance; maximum dilution of up to 62,111,801 shares at $1.61/share (51% of current 121.5M shares outstanding)

dilutioncash runway

Risk Factors

  • Potential dilution of up to 51% of current shares outstanding if full $100M is sold at current prices
  • Pre-revenue clinical-stage biotech with no approved products and ongoing net losses
  • ATM sales at various prices may pressure stock price over time

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-458736
Document: 0001193125-26-458736-index-headers.html0001193125-26-458736
Document: 0001193125-26-458736-index.html0001193125-26-458736
Document: 0001193125-26-458736.txt0001193125-26-458736

Track record

21 reports on FATE

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +30.25% at T+5 after the Nov 5, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 13, 20264d ago EFFECT Bearish 5/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
  2. Nov 12, 20264d ago 424B5 Bearish 4/10 Viewing Entry $1.28 Now $1.14 +10.94% settles Nov 20
  3. Nov 9, 20267d ago SC 13D/A Neutral 2/10 Entry $1.77 Now $1.14 −35.59% settles Nov 17
  4. Nov 5, 202611d ago S-3 Neutral 3/10 Entry $1.84 to $1.28 Now $1.14 −37.87% ▼ −30.25% −32.84% vs SPY
  5. Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
  6. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
  7. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  8. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.85 to $1.34 Now $1.14 −38.38% ▼ −27.57% −30.86% vs SPY
  9. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.09 to $1.61 Now $1.14 −45.45% ▼ −23.21% −22.29% vs SPY
  10. Nov 3, 202613d ago 144 Neutral 2/10 Entry $2.04 to $1.77 Now $1.14 −44.12% ▼ −13.24% −12.65% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 8h 2m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026